Abstract
Background Cardiac memory (CM) was known as a repolarization phenotype, an adaptive response of the heart on abnormal ventricular activation. The goal of this study was to determine factors associated with CM in patients receiving implantable cardioverter-defibrillators (ICD). We hypothesized that preexisted cardiac remodeling is associated with CM.
Methods Patients with structural heart disease (n=20; mean age 72.6±11.6 y; 80% male; mean left ventricular ejection fraction (LVEF) 31.7±7.6%; history of myocardial infarction (MI) in 75%, ventricular tachycardia (VT) in 85%) and preserved atrioventricular (AV) conduction received primary (80%) or secondary (20%) prevention dual-chamber ICD. Standard 12-lead ECG was recorded in AAI and DDD mode, immediately after ICD implant and after 7 days of right ventricular (RV) pacing in DDD mode with short AV delay. Direction (azimuth and elevation) and magnitude of spatial QRS, T, and ventricular gradient (SVG) vectors were measured immediately after implant and after 7 days of RV pacing. CM was quantified as the degree of alignment between QRSDDD-7 and TAAI-7 vectors (QRSDDD-7-TAAI-7 angle). Circular statistics and mixed models with a random slope and intercept were adjusted for days 1-7 change in cardiac activation, LVEF, known risk factors, and use of medications known to affect CM.
Results QRSDDD-7-TAAI-7 angle strongly correlated (circular r = −0.972; P<0.0001) with TAAI-7-TDDD-7 angle. Baseline TDDD-1 azimuth correlated with QRSAAI-7-QRSDDD-7 angle (circular r = 0.604; P<0.001). In the mixed models, history of MI (−180°(95%CI −320° to −40°); P=0.011) and female sex (−162°(95%CI −268° to −55°); P=0.003) counteracted CM-T azimuth changes (+132°(95%CI 80°-184°); P<0.0001). History of VT (+27(95%CI 4-46) mV*ms; P=0.007) amplified CM-T area increase (+15(95%CI 6 – 24) mV*ms; P<0.0001).
Conclusions Existing cardiac remodeling due to MI and VT significantly affects the degree of CM in response to RV pacing. Women develop less CM than men. Activation memory manifests as a smaller angle between QRS vectors of normal and abnormal activation.
Competing Interest Statement
The CAMI study was sponsored by Medtronic, Inc.
Clinical Trial
this is not a clinical trial
Funding Statement
This research was supported in part by the National Institute of Health HL118277 (LGT). The CAMI study was sponsored by Medtronic, Inc.
Author Declarations
All relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
Any clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.
Not Applicable
Footnotes
Funding Sources: This research was supported in part by the National Institute of Health HL118277 (LGT).
Conflict of interest: the CAMI study was sponsored by Medtronic, Inc.
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
1
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos